The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is a common endocrinological disorder in women with significant reproductive, metabolic, and psychological health implications. The lack of a specific diagnostic test poses challenges in making the diagnosis of PCOS, resulting in underdiagnosis and undertreatment. Anti-Mullerian hormone (AMH) synthesized by the pre-antral and small antral ovarian follicles appears to play an important role in the pathophysiology of PCOS, and serum AMH levels are often elevated in women with PCOS. The aim of this review is to inform the possibility of utilizing anti-Mullerian hormone either as a diagnostic test for PCOS or as an alternative diagnostic criterion in place of polycystic ovarian morphology, hyperandrogenism, and oligo-anovulation. Increased levels of serum AMH correlate highly with PCOS, polycystic ovarian morphology, hyperandrogenism, and oligo/amenorrhea. Additionally, serum AMH has high diagnostic accuracy as an isolated marker for PCOS or as a replacement for polycystic ovarian morphology.

Automated summary

Polycystic ovary syndrome (PCOS) is an endocrinological disorder with significant implications for women's reproductive, metabolic, and psychological health. The lack of a specific diagnostic test poses challenges in diagnosing PCOS, resulting in underdiagnosis and undertreatment. Anti-Mullerian hormone (AMH) appears to be a promising diagnostic marker for PCOS, with elevated levels correlating highly with PCOS features such as polycystic ovarian morphology, hyperandrogenism, and oligo/amenorrhea.